Effect of Naturally Random Allocation to Lower Low-density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both: a 2 × 2 Factorial Mendelian Randomization Study

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2015 Mar 16

PMID 25770315

Citations 153

Authors

Brian A Ference

Faisal Majeed

Raju Penumetcha

John M Flack

Robert D Brook

Affiliations

Soon will be listed here.

Abstract

Background: Considerable uncertainty exists as to whether lowering low-density lipoprotein cholesterol (LDL-C) by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitor (statin), will reduce the risk of coronary heart disease (CHD).

Objectives: This study evaluated the effect of naturally random allocation to lower LDL-C mediated by polymorphisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both (target of combination therapy) on the risk of CHD.

Methods: We constructed NPC1L1 and HMGCR genetic LDL-C scores to naturally randomize participants into 4 groups: reference, lower LDL-C mediated by NPC1L1 polymorphisms, lower LDL-C mediated by HMGCR polymorphisms, or lower LDL-C mediated by polymorphisms in both NPC1L1 and HMGCR. We compared the risk of CHD (fatal or nonfatal myocardial infarction) among each group using a 2 × 2 factorial mendelian randomization study design.

Results: A total of 108,376 persons (10,464 CHD events) from 14 studies were included. There were no significant differences in baseline characteristics among the 4 groups, thus confirming that allocation was random. Compared to the reference group, the NPC1L1 group had 2.4 mg/dl lower LDL-C and 4.8% lower risk of CHD (odds ratio [OR]: 0.952, 95% confidence interval [CI]: 0.920 to 0.985); whereas the HMGCR group had 2.9 mg/dl lower LDL-C and a similar 5.3% lower risk of CHD (OR: 0.947, 95% CI: 0.909 to 0.986). The group with lower LDL-C mediated by both NPC1L1 and HMGCR polymorphisms had 5.8 mg/dl additively lower LDL-C and a 10.8% log-linearly additive lower risk of CHD (OR: 0.892, 95% CI: 0.854 to 0.932).

Conclusions: The effect of lower LDL-C on the risk of CHD mediated by polymorphisms in NPC1L1, HMGCR, or both is approximately the same per unit lower LDL-C and log-linearly proportional to the absolute exposure to lower LDL-C.

Citing Articles

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis.

Yao Z, Qin D, Cao J, Gao C, Xi P, Li S BMC Cancer. 2025; 25(1):476.

PMID: 40087664 DOI: 10.1186/s12885-025-13824-7.

Causal relationship between drug target genes of LDL-cholesterol and coronary artery disease: drug target Mendelian randomization study.

Jee Y, Shin J, Ryu M, Song T Lipids Health Dis. 2025; 24(1):92.

PMID: 40082904 PMC: 11905656. DOI: 10.1186/s12944-025-02502-z.

Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk.

Wang L, Jiang F, Sun J, Zhao J, He Y, Gill D Int J Epidemiol. 2025; 54(2).

PMID: 40064167 PMC: 11893152. DOI: 10.1093/ije/dyaf020.

Association Between Hypoxia-Inducible Factor-1α and Neurological Diseases: A Bidirectional Two-Sample Mendelian Randomization Analysis.

Liang J, Du X, Wang M, Zheng H, Sun Y, Lin Y Brain Behav. 2025; 15(3):e70398.

PMID: 40022282 PMC: 11870835. DOI: 10.1002/brb3.70398.

Association between air pollution and osteoporosis: A Mendelian randomization study.

Ju M, Liu F, Deng T, Jia X, Xu W, Zhang F Medicine (Baltimore). 2025; 104(8):e41490.

PMID: 39993078 PMC: 11856944. DOI: 10.1097/MD.0000000000041490.

References

Kathiresan S, Melander O, Guiducci C, Surti A, Burtt N, Rieder M . Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40(2):189-97. PMC: 2682493. DOI: 10.1038/ng.75. View

Dadu R, Ballantyne C . Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014; 11(10):563-75. DOI: 10.1038/nrcardio.2014.84. View

Garcia-Calvo M, Lisnock J, Bull H, Hawes B, Burnett D, Braun M . The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102(23):8132-7. PMC: 1149415. DOI: 10.1073/pnas.0500269102. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

Stitziel N, Won H, Morrison A, Peloso G, Do R, Lange L . Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014; 371(22):2072-82. PMC: 4335708. DOI: 10.1056/NEJMoa1405386. View

Cannon C, Giugliano R, Blazing M, Harrington R, Peterson J, McCrary Sisk C . Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008; 156(5):826-32. DOI: 10.1016/j.ahj.2008.07.023. View

Mailman M, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R . The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007; 39(10):1181-6. PMC: 2031016. DOI: 10.1038/ng1007-1181. View

Morrone D, Weintraub W, Toth P, Hanson M, Lowe R, Lin J . Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012; 223(2):251-61. DOI: 10.1016/j.atherosclerosis.2012.02.016. View

10.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

11.

Blazing M, Giugliano R, Cannon C, Musliner T, Tershakovec A, White J . Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014; 168(2):205-12.e1. DOI: 10.1016/j.ahj.2014.05.004. View

12.

Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J . Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370(9602):1829-39. DOI: 10.1016/S0140-6736(07)61778-4. View

13.

Ference B, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A . Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25):2631-9. DOI: 10.1016/j.jacc.2012.09.017. View

14.

Teslovich T, Musunuru K, Smith A, Edmondson A, Stylianou I, Koseki M . Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466(7307):707-13. PMC: 3039276. DOI: 10.1038/nature09270. View

15.

Ginsberg H, Elam M, Lovato L, Crouse 3rd J, Leiter L, Linz P . Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-74. PMC: 2879499. DOI: 10.1056/NEJMoa1001282. View

16.

Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes T, Thompson J . Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012; 45(1):25-33. PMC: 3679547. DOI: 10.1038/ng.2480. View

17.

Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3):203-12. DOI: 10.1056/NEJMoa1300955. View

18.

Lawlor D, Harbord R, Sterne J, Timpson N, Davey Smith G . Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2007; 27(8):1133-63. DOI: 10.1002/sim.3034. View

19.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

20.

Willer C, Schmidt E, Sengupta S, Peloso G, Gustafsson S, Kanoni S . Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45(11):1274-1283. PMC: 3838666. DOI: 10.1038/ng.2797. View